vTv Therapeutics begins Phase III trial of azeliragon to treat mild Alzheimer’s disease
The initiation of this Phase III trial follows a Phase II trial, which showed positive results in slowing cognitive decline with 5mg/day of azeliragon in patients with mild
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.